Access to PCSK9 Inhibitors

Rev Cardiovasc Med. 2018;19(S1):S47-S50. doi: 10.3909/ricm19S1S0006.

Authors

Seth J Baum¹, Norman E Lepor², Jennifer G Robinson³

Affiliations

¹ Preventive Cardiology, Inc., Boca Raton, FL.
² Cedars-Sinai Heart Institute, Los Angeles, CA.
³ Departments of Epidemiology & Medicine, University of Iowa College of Public Health and Carver College of Medicine, Iowa City, IA.

PMID: 30207557
DOI: 10.3909/ricm19S1S0006

No abstract available

Publication types

Introductory Journal Article

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents / supply & distribution*
Anticholesteremic Agents / therapeutic use*
Biomarkers / blood
Cholesterol, LDL / blood*
Clinical Decision-Making
Dyslipidemias / blood
Dyslipidemias / diagnosis
Dyslipidemias / drug therapy*
Dyslipidemias / enzymology
Evidence-Based Medicine
Health Services Accessibility*
Humans
PCSK9 Inhibitors*
Patient Selection
Proprotein Convertase 9 / metabolism
Serine Proteinase Inhibitors / supply & distribution*
Serine Proteinase Inhibitors / therapeutic use*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Biomarkers
Cholesterol, LDL
PCSK9 Inhibitors
Serine Proteinase Inhibitors
PCSK9 protein, human
Proprotein Convertase 9
evolocumab
alirocumab